# Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Canonical URL: https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-wednes-8f4fa5e8
Ticker: VCEL
Company: Vericel Corp
Source: Vericel Corp
Published: 2026-01-06 13:30 EST
## Summary

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe...

## Article Body
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44 th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI ® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel ® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid ® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com .

Epicel ® and MACI ® and MACI Arthro ® are registered trademarks of Vericel Corporation. NexoBrid ® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2026 Vericel Corporation. All rights reserved.

Investor Contact: Eric Burns ir@vcel.com +1 (734) 418-4411
## Recent Company News
- 2026-07-16 12:30 EST — [Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026](https://biopharmsignal.com/news/VCEL/vericel-to-report-second-quarter-2026-financial-results-on-july-30-2026-99cb171e) — Source: Vericel Corp
- 2026-06-09 12:30 EST — [Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026](https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-2026-truist-securities-medtech-conference-on-tuesday-j-4259fa3f) — Source: Vericel Corp
- 2026-05-07 11:45 EST — [Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance](https://biopharmsignal.com/news/VCEL/vericel-reports-first-quarter-2026-financial-results-and-raises-full-year-financ-80a8b132) — Source: Vericel Corp
- 2026-04-23 12:30 EST — [Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/VCEL/vericel-to-report-first-quarter-2026-financial-results-on-may-7-2026-fb241894) — Source: Vericel Corp
- 2026-04-02 18:40 EST — [Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid](https://biopharmsignal.com/news/VCEL/vericel-announces-barda-award-valued-at-up-to-197-million-for-procurement-and-ad-adaf00c4) — Source: Vericel Corp
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)